Noumed Pharmaceuticals is establishing an A$85 million manufacturing facility in South Australia, thanks to funding support from the Australian Government's Modern Manufacturing Initiative.
First manufacturing facility in Australia
Noumed Pharmaceuticals, part of UK-based Noumed Life Sciences, specialises in manufacturing generic pharmaceuticals.
The new manufacturing facility is Noumed's first in Australia and will be based at Salisbury South. The company currently manufactures all of the products it supplies the Australian market offshore, but will become almost entirely self-sufficient when the new facility opens by 2025.
Noumed will manufacture 40 million units of tablets, liquids and creams a year locally. These include cold and flu tablets, painkillers, topical creams, prescription and lifesaving medications.
The Noumed facility will have a strong focus on research and development, in addition to manufacturing. This will create job opportunities for scientists, pharmacy graduates, logistics experts and engineers. There will also be collaboration opportunities with local research institutions.
The project is expected to create up to 250 jobs during construction. A further 180 ongoing positions will be created when the facility begins operations.
About the Modern Manufacturing Strategy
Noumed received a A$20 million grant from the Australian Government's Modern Manufacturing Initiative to support the facility's construction. The Initiative is a key element of the Government's A$1.5 billion Modern Manufacturing Strategy. The Strategy aims to help the Australian manufacturing industry to scale up and become more competitive, sustainable and resilient.
Applications are now open for the A$800 million Manufacturing Collaboration Stream, which provides co-funding for large, transformational projects. International investors, businesses and researchers are invited to partner with Australian organisations
